The soluble guanylate cyclase activator runcaciguat significantly improved albuminuria in patients with CKD on top of RAS inhibitor and SGLT2 inhibitor treatment. Runcaciguat, an oral soluble ...

This phase 1–2, randomised, double-blind, placebo-controlled trial enrolled 130 patients aged 18 or older with confirmed ...

Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...

A new study published in the Journal of American Medical Association showed that individuals with heart failure with ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

Linaclotide, a guanylate cyclase C receptor agonist, has shown promising efficacy as a treatment for chronic constipation in a phase IIb, double-blinded, placebo-controlled, dose-ranging trial.

Its primary products include a portfolio of soluble guanylate cyclase (sGC) stimulators aimed at generating revenues and advancing its strategic initiatives. YTD Price Performance: 5.37% Average ...

Owing to these mechanisms of action, Ibsrela is a first-in-class IBS-C med, with the other four approved therapies classified as guanylate cyclase-C [GCC] agonists. The latter drugs promote the ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) has been given an average rating of “Moderate Buy” by the six research firms that are covering the company, MarketBeat.com reports. Three ...

inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability across the spectrum of pulmonary ...